Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Role of adjuvant chemotherapy in the management of stage IC ovarian granulosa cell tumors.

Nasioudis D, Ko EM, Haggerty AF, Giuntoli RL 2nd, Burger RA, Morgan MA, Latif NA.

Gynecol Oncol Rep. 2019 Apr 17;28:145-148. doi: 10.1016/j.gore.2019.04.004. eCollection 2019 May.

2.

Adjuvant chemotherapy is not associated with a survival benefit for patients with early stage mucinous ovarian carcinoma.

Nasioudis D, Haggerty AF, Giuntoli RL 2nd, Burger RA, Morgan MA, Ko EM, Latif NA.

Gynecol Oncol. 2019 May 30. pii: S0090-8258(19)31233-8. doi: 10.1016/j.ygyno.2019.05.009. [Epub ahead of print]

PMID:
31155308
3.

Isolated distant lymph node metastases in ovarian cancer. Should a new substage be created?

Nasioudis D, Ko EM, Haggerty AF, Giuntoli RL 2nd, Burger RA, Morgan MA, Latif NA.

Gynecol Oncol Rep. 2019 Mar 13;28:86-90. doi: 10.1016/j.gore.2019.03.008. eCollection 2019 May.

4.

Treat-and-Release Emergency Department Utilization by Patients With Gynecologic Cancers.

Albright BB, Delgado MK, Latif NA, Giuntoli RL 2nd, Ko EM, Haggerty AF.

J Oncol Pract. 2019 May;15(5):e428-e438. doi: 10.1200/JOP.18.00639. Epub 2019 Apr 9.

PMID:
30964736
5.

Ovarian preservation for low-grade endometrial stromal sarcoma: a systematic review of the literature and meta-analysis.

Nasioudis D, Ko EM, Kolovos G, Vagios S, Kalliouris D, Giuntoli RL.

Int J Gynecol Cancer. 2019 Jan;29(1):126-132. doi: 10.1136/ijgc-2018-000063.

PMID:
30640694
6.

Readmission After Gynecologic Surgery: A Comparison of Procedures for Benign and Malignant Indications.

Cory L, Latif N, Brensinger C, Zhang X, Giuntoli RL 2nd, Burger RA, Morgan M, Ko E.

Obstet Gynecol. 2017 Aug;130(2):285-295. doi: 10.1097/AOG.0000000000002141.

PMID:
28697106
7.

Survival implications of time to surgical treatment of endometrial cancers.

Shalowitz DI, Epstein AJ, Buckingham L, Ko EM, Giuntoli RL 2nd.

Am J Obstet Gynecol. 2017 Mar;216(3):268.e1-268.e18. doi: 10.1016/j.ajog.2016.11.1050. Epub 2016 Dec 9.

PMID:
27939327
8.

Non-surgical management of ovarian cancer: Prevalence and implications.

Shalowitz DI, Epstein AJ, Ko EM, Giuntoli RL 2nd.

Gynecol Oncol. 2016 Jul;142(1):30-37. doi: 10.1016/j.ygyno.2016.04.026. Epub 2016 May 5.

PMID:
27107721
9.

VEGF Potentiates GD3-Mediated Immunosuppression by Human Ovarian Cancer Cells.

Tiper IV, Temkin SM, Spiegel S, Goldblum SE, Giuntoli RL 2nd, Oelke M, Schneck JP, Webb TJ.

Clin Cancer Res. 2016 Aug 15;22(16):4249-58. doi: 10.1158/1078-0432.CCR-15-2518. Epub 2016 Apr 13.

10.

Geographic access to gynecologic cancer care in the United States.

Shalowitz DI, Vinograd AM, Giuntoli RL 2nd.

Gynecol Oncol. 2015 Jul;138(1):115-20. doi: 10.1016/j.ygyno.2015.04.025. Epub 2015 Apr 25.

PMID:
25922191
11.

Does death anxiety affect end-of-life care discussions?

Brown AJ, Shen MJ, Ramondetta LM, Bodurka DC, Giuntoli RL 2nd, Diaz-Montes T.

Int J Gynecol Cancer. 2014 Oct;24(8):1521-6. doi: 10.1097/IGC.0000000000000250.

12.

A comparison of colorimetric versus fluorometric sentinel lymph node mapping during robotic surgery for endometrial cancer.

Sinno AK, Fader AN, Roche KL, Giuntoli RL 2nd, Tanner EJ.

Gynecol Oncol. 2014 Aug;134(2):281-6. doi: 10.1016/j.ygyno.2014.05.022. Epub 2014 Jun 2.

PMID:
24882555
13.

Detection of circulating tumor DNA in early- and late-stage human malignancies.

Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih lM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA Jr.

Sci Transl Med. 2014 Feb 19;6(224):224ra24. doi: 10.1126/scitranslmed.3007094.

14.

A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor.

McDermott DH, Liu Q, Velez D, Lopez L, Anaya-O'Brien S, Ulrick J, Kwatemaa N, Starling J, Fleisher TA, Priel DA, Merideth MA, Giuntoli RL, Evbuomwan MO, Littel P, Marquesen MM, Hilligoss D, DeCastro R, Grimes GJ, Hwang ST, Pittaluga S, Calvo KR, Stratton P, Cowen EW, Kuhns DB, Malech HL, Murphy PM.

Blood. 2014 Apr 10;123(15):2308-16. doi: 10.1182/blood-2013-09-527226. Epub 2014 Feb 12.

15.

Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma?

Ricci S, Giuntoli RL 2nd, Eisenhauer E, Lopez MA, Krill L, Tanner EJ 3rd, Gehrig PA, Havrilesky LJ, Secord AA, Levinson K, Frasure H, Celano P, Fader AN.

Gynecol Oncol. 2013 Dec;131(3):629-33. doi: 10.1016/j.ygyno.2013.08.037. Epub 2013 Sep 7.

PMID:
24016408
16.

A pilot study of surgical training using a virtual robotic surgery simulator.

Tergas AI, Sheth SB, Green IC, Giuntoli RL 2nd, Winder AD, Fader AN.

JSLS. 2013 Apr-Jun;17(2):219-26. doi: 10.4293/108680813X13654754535872.

17.

Primary uterine cancer in Maryland: impact of distance on access to surgical care at high-volume hospitals.

Gunderson CC, Tergas AI, Fleury AC, Diaz-Montes TP, Giuntoli RL 2nd.

Int J Gynecol Cancer. 2013 Sep;23(7):1244-51. doi: 10.1097/IGC.0b013e31829ea002.

PMID:
23899587
18.

Comparison of current staging systems and a novel staging system for uterine leiomyosarcoma.

Giuntoli RL 2nd, Lessard-Anderson CR, Gerardi MA, Kushnir CL, Cliby WA, Metzinger DS, Gostout BS.

Int J Gynecol Cancer. 2013 Jun;23(5):869-76. doi: 10.1097/IGC.0b013e3182916a1e.

PMID:
23669444
19.

Cervical cancer.

Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Cohn D, Crispens MA, DuPont N, Eifel PJ, Gaffney DK, Giuntoli RL 2nd, Han E, Huh WK, Lurain JR 3rd, Martin L, Morgan MA, Mutch D, Remmenga SW, Reynolds RK, Small W Jr, Teng N, Tillmanns T, Valea FA, McMillian NR, Hughes M; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2013 Mar 1;11(3):320-43.

PMID:
23486458
20.

Molecular identification of GD3 as a suppressor of the innate immune response in ovarian cancer.

Webb TJ, Li X, Giuntoli RL 2nd, Lopez PH, Heuser C, Schnaar RL, Tsuji M, Kurts C, Oelke M, Schneck JP.

Cancer Res. 2012 Aug 1;72(15):3744-52. doi: 10.1158/0008-5472.CAN-11-2695. Epub 2012 May 30.

21.

Importance and timing of end-of-life care discussions among gynecologic oncology patients.

Díaz-Montes TP, Johnson MK, Giuntoli RL 2nd, Brown AJ.

Am J Hosp Palliat Care. 2013 Feb;30(1):59-67. doi: 10.1177/1049909112444156. Epub 2012 Apr 24.

PMID:
22531151
22.

Volume-Based Care among Young Women Diagnosed with Uterine Cancer.

Diaz-Montes TP, Giuntoli RL.

ISRN Surg. 2011;2011:541461. doi: 10.5402/2011/541461. Epub 2011 Nov 24.

23.

Stage I noninvasive and minimally invasive uterine serous carcinoma: comprehensive staging associated with improved survival.

Giuntoli RL 2nd, Gerardi MA, Yemelyanova AV, Ueda SM, Fleury AC, Diaz-Montes TP, Bristow RE.

Int J Gynecol Cancer. 2012 Feb;22(2):273-9. doi: 10.1097/IGC.0b013e318238df4d.

PMID:
22146771
24.

Upper abdominal cytoreduction and thoracoscopy for advanced epithelial ovarian cancer: unanswered questions and the impact on treatment.

Fleury AC, Kushnir CL, Giuntoli RL 2nd, Spirtos NM.

BJOG. 2012 Jan;119(2):202-6. doi: 10.1111/j.1471-0528.2011.03197.x. Epub 2011 Nov 15. Review.

25.

Feasibility of intravenous gemcitabine and an intraperitoneal platinum agent in the treatment of ovarian cancer.

Giuntoli RL 2nd, Bristow RE, Diaz-Montes TP, Armstrong DK.

J Chemother. 2011 Jun;23(3):163-7.

26.

Comparison of candidate serologic markers for type I and type II ovarian cancer.

Lu D, Kuhn E, Bristow RE, Giuntoli RL 2nd, Kjær SK, Shih IeM, Roden RB.

Gynecol Oncol. 2011 Sep;122(3):560-6. doi: 10.1016/j.ygyno.2011.05.039. Epub 2011 Jun 24.

27.

Evolution of a trophoblastic tumor from an endometrioid carcinoma--a morphological and molecular analysis.

Olson MT, Gocke CD, Giuntoli RL 2nd, Shih IeM.

Int J Gynecol Pathol. 2011 Mar;30(2):117-20. doi: 10.1097/PGP.0b013e3181f5ce68.

PMID:
21293290
28.

Surgical technique of diaphragm full-thickness resection and trans-diaphragmatic decompression of pneumothorax during cytoreductive surgery for ovarian cancer.

Bashir S, Gerardi MA, Giuntoli RL 2nd, Montes TP, Bristow RE.

Gynecol Oncol. 2010 Nov;119(2):255-8. doi: 10.1016/j.ygyno.2010.07.017. Epub 2010 Aug 23.

PMID:
20739051
29.

Correlation of extreme drug resistant assay results and progression-free survival following intraperitoneal chemotherapy for advanced ovarian cancer.

Pant AC, Diaz-Montes T, Tanner E, Ahmad S, Giuntoli RL, Holloway RW, Bristow RE.

J Chemother. 2010 Aug;22(4):270-4.

PMID:
20685633
30.

Computed tomographic peritoneography prior to intraperitoneal chemotherapy in advanced Müllerian cancer: a pilot study.

Barlin JN, Bristow RE, Bleich K, Giuntoli RL 2nd, Thompson S, Diaz-Montes TP.

Clin Imaging. 2010 May-Jun;34(3):191-5. doi: 10.1016/j.clinimag.2009.05.009.

PMID:
20416483
31.

Identification and characterization of a spontaneous ovarian carcinoma in Lewis rats.

Sharrow AC, Ronnett BM, Thoburn CJ, Barber JP, Giuntoli RL 2nd, Armstrong DK, Jones RJ, Hess AD.

J Ovarian Res. 2010 Mar 31;3:9. doi: 10.1186/1757-2215-3-9.

32.

Trophoblastic neoplasms express fatty acid synthase, which may be a therapeutic target via its inhibitor C93.

Ueda SM, Mao TL, Kuhajda FP, Vasoontara C, Giuntoli RL, Bristow RE, Kurman RJ, Shih IeM.

Am J Pathol. 2009 Dec;175(6):2618-24. doi: 10.2353/ajpath.2009.081162. Epub 2009 Nov 5.

33.

Impact of surgeon and hospital ovarian cancer surgical case volume on in-hospital mortality and related short-term outcomes.

Bristow RE, Zahurak ML, Diaz-Montes TP, Giuntoli RL, Armstrong DK.

Gynecol Oncol. 2009 Dec;115(3):334-8. doi: 10.1016/j.ygyno.2009.08.025. Epub 2009 Sep 18.

PMID:
19766295
34.

Analysis of contemporary trends in access to high-volume ovarian cancer surgical care.

Bristow RE, Puri I, Diaz-Montes TP, Giuntoli RL, Armstrong DK.

Ann Surg Oncol. 2009 Dec;16(12):3422-30. doi: 10.1245/s10434-009-0680-5. Epub 2009 Aug 27.

PMID:
19711131
35.

Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity.

Giuntoli RL 2nd, Webb TJ, Zoso A, Rogers O, Diaz-Montes TP, Bristow RE, Oelke M.

Anticancer Res. 2009 Aug;29(8):2875-84.

36.

Secondary cytoreductive surgery including rectosigmoid colectomy for recurrent ovarian cancer: operative technique and clinical outcome.

Bristow RE, Peiretti M, Gerardi M, Zanagnolo V, Ueda S, Diaz-Montes T, Giuntoli RL 2nd, Maggioni A.

Gynecol Oncol. 2009 Aug;114(2):173-7. doi: 10.1016/j.ygyno.2009.05.004. Epub 2009 May 31.

PMID:
19482344
37.

Metastatic leiomyosarcoma diagnosed after uterine artery embolization.

Posy HE, Elkas JC, Yemelyanova AV, Diaz-Montes TP, Bristow RE, Giuntoli RL 2nd.

Eur J Gynaecol Oncol. 2009;30(2):199-202.

PMID:
19480255
38.

Ascites specific inhibition of CD1d-mediated activation of natural killer T cells.

Webb TJ, Giuntoli RL 2nd, Rogers O, Schneck J, Oelke M.

Clin Cancer Res. 2008 Dec 1;14(23):7652-8. doi: 10.1158/1078-0432.CCR-08-1468.

39.

Feasibility and economic impact of a clinical pathway for pap test utilization in Gynecologic Oncology practice.

Santillan A, Govan L, Zahurak ML, Diaz-Montes TP, Giuntoli RL 2nd, Bristow RE.

Gynecol Oncol. 2008 Jun;109(3):388-93. doi: 10.1016/j.ygyno.2008.01.006. Epub 2008 Apr 10.

PMID:
18405946
40.

Transverse colectomy in ovarian cancer surgical cytoreduction: operative technique and clinical outcome.

Bristow RE, Peiretti M, Zanagnolo V, Salani R, Giuntoli RL 2nd, Maggioni A.

Gynecol Oncol. 2008 Jun;109(3):364-9. doi: 10.1016/j.ygyno.2008.02.020. Epub 2008 Apr 8.

PMID:
18396322
41.

Diagnostic criteria for uterine smooth muscle tumors: leiomyoma variants associated with malignant behavior.

Giuntoli RL 2nd, Gostout BS, DiMarco CS, Metzinger DS, Keeney GL.

J Reprod Med. 2007 Nov;52(11):1001-10.

PMID:
18161397
42.

A clinical pathway for patients undergoing primary cytoreductive surgery with rectosigmoid colectomy for advanced ovarian and primary peritoneal cancers.

Gerardi MA, Santillan A, Meisner B, Zahurak ML, Diaz Montes TP, Giuntoli RL 2nd, Bristow RE.

Gynecol Oncol. 2008 Feb;108(2):282-6. Epub 2007 Nov 19.

PMID:
18023851
43.

Surgical management of mesenteric lymph node metastasis in patients undergoing rectosigmoid colectomy for locally advanced ovarian carcinoma.

Salani R, Diaz-Montes T, Giuntoli RL, Bristow RE.

Ann Surg Oncol. 2007 Dec;14(12):3552-7. Epub 2007 Sep 25.

PMID:
17896149
44.

Survival impact of multiple bowel resections in patients undergoing primary cytoreductive surgery for advanced ovarian cancer: a case-control study.

Salani R, Zahurak ML, Santillan A, Giuntoli RL 2nd, Bristow RE.

Gynecol Oncol. 2007 Dec;107(3):495-9. Epub 2007 Sep 12.

PMID:
17854870
45.

Concentration of uterine cancer surgical care among the elderly: a population-based perspective.

Díaz-Montes TP, Zahurak ML, Giuntoli RL 2nd, Bristow RE.

Gynecol Oncol. 2007 Dec;107(3):436-40. Epub 2007 Aug 31.

PMID:
17764726
46.

Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.

Bristow RE, Santillan A, Salani R, Diaz-Montes TP, Giuntoli RL 2nd, Meisner BC, Armstrong DK, Frick KD.

Gynecol Oncol. 2007 Sep;106(3):476-81. Epub 2007 Aug 3.

PMID:
17688927
47.

Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma.

Santillan A, Kim YW, Zahurak ML, Gardner GJ, Giuntoli RL 2nd, Shih IM, Bristow RE.

Int J Gynecol Cancer. 2007 May-Jun;17(3):601-6.

PMID:
17504374
48.

Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma.

Giuntoli RL 2nd, Garrett-Mayer E, Bristow RE, Gostout BS.

Gynecol Oncol. 2007 Jul;106(1):82-8. Epub 2007 Apr 16.

PMID:
17434579
49.

The role of cytoreductive surgery for colon cancer metastatic to the ovary.

McCormick CC, Giuntoli RL 2nd, Gardner GJ, Schulick RD, Judson K, Ronnett BM, Vang R, Bristow RE.

Gynecol Oncol. 2007 Jun;105(3):791-5. Epub 2007 Apr 6.

PMID:
17408727
50.

Centralization of care for patients with advanced-stage ovarian cancer: a cost-effectiveness analysis.

Bristow RE, Santillan A, Diaz-Montes TP, Gardner GJ, Giuntoli RL 2nd, Meisner BC, Frick KD, Armstrong DK.

Cancer. 2007 Apr 15;109(8):1513-22.

Supplemental Content

Loading ...
Support Center